Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.

Aboud M, Kaplan R, Lombaard J, et al. Lancet Infect Dis. 2019;19(3):253-264.

Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.

Ambrosioni J, Rojas Liévano J, Berrocal L, et al. J Antimicrob Chemother. 2022;77(4):1133-1139.

Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options.

Bajema KL, Nance RM, Delaney JAC, et al; Centers for AIDS Research Clinical Network of Integrated Systems (CNICS). AIDS. 2020;34(14):2051-2059.

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.

Boyd MA, Kumarasamy N, Moore CL, et al; SECOND-LINE Study Group. Lancet. 2013;381(9883):2091-2099.

The management of treatment-experienced HIV patients (including virologic failure and switches).

Cutrell J, Jodlowski T, Bedimo R. Ther Adv Infectious Dis. 2020;7:2049936120901395.

Lenacapavir: a first-in-class HIV-1 capsid inhibitor.

Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS. Curr Opin HIV AIDS. 2022;17(1):15-21.

Phase 3 study of ibalizumab for multidrug-resistant HIV-1.

Emu B, Fessel J, Schrader S, et al. N Engl J Med. 2018;379(7):645-654.

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.

Lataillade M, Lalezari JP, Kozal M, et al. Lancet HIV. 2020;7(11):e740-e751.

Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: A retrospective analysis.

Mazzitelli M, Sasset L, Leoni D, Putaggio C, Cattelan AM. Medicine (Baltimore). 2021;100(52):e28488.

Long-acting lenacapavir in people with multidrug resistant HIV-1: week 52 results.

Ogbuagu O, Segal-Maurer S, Brinson C, et al. Presented at: Conference on Retroviruses and Opportunistic Infections; February 12-16, 2022; virtual conference. Abstract 491.

Potent antiviral activity of lenacapavir in phase 2/3 in heavily ART-experienced PWH.

Segal-Maurer S, Castagna A, Berhe M, et al.  CROI. March 6-10, 2021; Virtual Conference. Abstract 127.

The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses.

Wei X, Liang C, Götte M, Wainberg MA. AIDS. 2002;16(18):2391-2398.

Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients.

Vizcarra P, Fontecha M, Monsalvo M, Vivancos MJ, Rojo A, Casado JL. Antivir Ther. 2019;24(6):467-471.